guest ::
| Home > Publications database > Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. > print |
| Home > Publications database > Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. > print |
| 001 | 303443 | ||
| 005 | 20250817022053.0 | ||
| 024 | 7 | _ | |a 10.1016/j.trecan.2025.07.005 |2 doi |
| 024 | 7 | _ | |a pmid:40783365 |2 pmid |
| 024 | 7 | _ | |a 2405-8033 |2 ISSN |
| 024 | 7 | _ | |a 2405-8025 |2 ISSN |
| 024 | 7 | _ | |a altmetric:180167133 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01656 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Braun, Lukas M |0 P:(DE-He78)b5f03547ed92823fcfbfc70c5ec2712e |b 0 |u dkfz |
| 245 | _ | _ | |a Clinical perspective and treatment of immune-related colitis after cancer immunotherapy. |
| 260 | _ | _ | |a Amsterdam |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1754913055_15678 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a epub |
| 520 | _ | _ | |a Targeting negative regulators of immunity with immune-checkpoint inhibitors (ICIs) has led to significant survival benefit in patients with various cancer entities. ICI therapy disrupts mechanisms of immune tolerance, which induces inflammatory toxicities in different target organs, summarized as immune-related adverse events (irAEs) in some patients. ICI-colitis relies on the activation of intestinal tissue-resident memory T cells (TRM cells) and is one of the most frequently observed immune-related toxicities; it can be fatal if untreated. The disease is associated with highly cytotoxic intestinal T cells and inflammatory myeloid activation. Current clinical management relies on broad immunosuppression, potentially reducing antitumor immunity. Ideal future therapies for irAEs will uncouple immunosuppressive activities in the inflamed target organ and the tumor microenvironment. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a anticancer immunity |2 Other |
| 650 | _ | 7 | |a cancer immunotherapy |2 Other |
| 650 | _ | 7 | |a checkpoint blockade |2 Other |
| 650 | _ | 7 | |a colitis |2 Other |
| 650 | _ | 7 | |a immune-checkpoint inhibitor |2 Other |
| 650 | _ | 7 | |a immune-related adverse events |2 Other |
| 650 | _ | 7 | |a immune-related colitis |2 Other |
| 650 | _ | 7 | |a inflammatory toxicities |2 Other |
| 700 | 1 | _ | |a Lu, Yunjie |b 1 |
| 700 | 1 | _ | |a Zeiser, Robert |0 P:(DE-HGF)0 |b 2 |
| 773 | _ | _ | |a 10.1016/j.trecan.2025.07.005 |g p. S2405803325001748 |0 PERI:(DE-600)2852626-0 |p nn |t Trends in cancer |v nn |y 2025 |x 2405-8033 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:303443 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)b5f03547ed92823fcfbfc70c5ec2712e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-18 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-18 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-18 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b TRENDS CANCER : 2022 |d 2024-12-18 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b TRENDS CANCER : 2022 |d 2024-12-18 |
| 920 | 1 | _ | |0 I:(DE-He78)FR01-20160331 |k FR01 |l DKTK Koordinierungsstelle Freiburg |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FR01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|